# Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

> **NCT05819398** · PHASE2,PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 209 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Spesolimab i.v.
- **DRUG:** Spesolimab s.c.
- **DRUG:** Placebo matching Spesolimab i.v.
- **DRUG:** Placebo matching Spesolimab s.c.

## Key facts

- **NCT ID:** NCT05819398
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-17
- **Primary completion:** 2024-08-01
- **Final completion:** 2025-03-31
- **Target enrollment:** 209 (ACTUAL)
- **Last updated:** 2025-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05819398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05819398, "Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05819398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*